Estradiol Gel (Divigel/Elestrin): History, Development, and How It Works

Why Transdermal Estradiol Was Needed

Oral estrogen has been available since the 1940s, but it has a fundamental pharmacological problem. Every milligram you swallow passes through the portal circulation before reaching systemic tissues, triggering a surge in hepatic protein synthesis, including clotting factors, sex hormone-binding globulin, and C-reactive protein. For women with cardiovascular risk factors, a personal or family history of clots, or migraine with aura, that hepatic amplification carries real consequences.

Researchers recognized by the 1970s that delivering estradiol across the skin would sidestep this hepatic first-pass effect entirely. The compound that arrived in the bloodstream would be chemically identical to ovarian estradiol, 17β-estradiol, rather than the conjugated equine estrogens or synthetic ethinyl estradiol dominant in early formulations.

The transdermal patch entered European markets in the 1980s and gained FDA approval in the United States in 1986. Patches worked, but women reported adhesion problems, skin reactions at the patch site, and the visible presence of a device under clothing. Gel offered a solution: a clear, alcohol-based medium that spread over a wider skin surface, dried quickly, and left nothing visible.

The Pharmaceutical Problem Gel Had to Solve

Getting estradiol across intact skin in a therapeutically meaningful amount is not straightforward. The stratum corneum, the outermost epidermal layer, is designed to keep molecules out. Estradiol is lipophilic enough to cross this barrier, but absorption is slow and variable without a carefully engineered vehicle.

Early European gel formulations used hydroalcoholic bases with penetration-enhancing excipients such as carbomer polymers and propylene glycol. The alcohol evaporates rapidly after application, leaving a thin estradiol-rich film that partitions into the lipid-rich stratum corneum and creates a depot that releases drug over 24 hours.

European Precedent Before U.S. Approval

Oestrogel, a 0.06% estradiol gel, launched in several European countries during the 1980s and accumulated decades of real-world use data before U.S.-specific formulations were developed. That evidence base was not ignored by American regulators. The pharmacokinetic studies submitted in support of Elestrin and Divigel drew on both European data and new U.S. Trials designed to meet current FDA bioavailability standards.

How Estradiol Gel Works: Mechanism of Action

Estradiol gel works by delivering 17β-estradiol transdermally. Once the vehicle dries, estradiol diffuses through the stratum corneum into the viable epidermis and then into dermal capillaries, entering systemic circulation without hepatic pre-processing.

Receptor Biology

Estradiol binds estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) with high affinity. In the hypothalamus and anterior pituitary, estradiol suppresses gonadotropin-releasing hormone pulsatility and reduces LH and FSH secretion, the mechanism underlying its contraceptive effect in premenopausal women and its suppression of hot-flush frequency in postmenopausal women. In the vaginal epithelium, bone, and cardiovascular endothelium, ERα activation drives the tissue responses that define clinical benefit: relief of genitourinary syndrome, reduction in bone resorption, and vasodilatory effects.

The hypothalamic thermoregulatory zone, sometimes called the thermoneutral zone, narrows during estrogen withdrawal. Hot flushes occur when core temperature fluctuates within this narrowed zone and triggers inappropriate heat-dissipation responses. Estradiol widens that zone again, reducing flush frequency and severity.

What "Bioidentical" Means Pharmacologically

Divigel and Elestrin both contain 17β-estradiol, the same molecule produced by the human ovary. This is distinct from conjugated equine estrogens (CEE), which contain a mixture of equine estrogens including equilin and equilenin. It is also distinct from synthetic ethinyl estradiol, which carries a 17-alpha ethinyl group that prevents hepatic metabolism and produces supraphysiological hepatic estrogen effects. The term "bioidentical" in a regulatory context means structurally identical to endogenous human estradiol; it does not mean the product is unregulated or compounded.

Pharmacokinetics: What the Gel Formulation Does Differently

Applied once daily to the upper thigh (Divigel) or upper arm (Elestrin), the gel produces serum estradiol levels that rise gradually over roughly 2-4 hours and remain relatively steady across a 24-hour dosing interval. This avoids the peak-and-trough pattern seen with twice-weekly patches and the sharp oral absorption spike.

Because absorption bypasses the liver, sex hormone-binding globulin (SHBG) is not substantially induced, leaving a higher proportion of estradiol in its biologically active unbound form. Hepatic coagulation factor synthesis, specifically factors VII and X, is minimally affected compared with oral estrogen. This pharmacokinetic distinction underlies the VTE safety signal discussed below.

The Development of Divigel and Elestrin

Elestrin's Path to FDA Approval

Elestrin (0.06% estradiol gel) is manufactured by BioSante Pharmaceuticals, later acquired by ANI Pharmaceuticals and distributed through Meda Pharmaceuticals in the U.S. The key Phase 3 trial enrolled 222 postmenopausal women with at least seven moderate-to-severe hot flushes per day. After 12 weeks, 0.87 g once daily reduced moderate-to-severe flush frequency by approximately 74% from baseline, compared with a 51% reduction in the placebo arm. The FDA approved Elestrin in October 2006.

Divigel's Path to FDA Approval

Divigel (0.1% estradiol gel) was developed by Upsher-Smith Laboratories and later distributed by Vertical Pharmaceuticals and, through generic agreements, by Mylan. The key trial enrolled postmenopausal women experiencing at least seven moderate-to-severe vasomotor symptoms per day, randomized to 0.25 g, 0.5 g, or 1.0 g Divigel once daily or placebo over 12 weeks. All three active doses produced statistically significant reductions in flush frequency relative to placebo; the 0.5 g dose reduced flush frequency by approximately 76% from baseline at week 12, the strongest response in the trial. FDA approved Divigel in January 2007.

The Role of the WHI in Reshaping Transdermal Development

The Women's Health Initiative (WHI) results, published in 2002 in JAMA, showed that oral CEE plus medroxyprogesterone acetate increased breast cancer incidence and cardiovascular events. The results caused a sharp decline in hormone therapy prescribing overall. They also focused attention on whether route of administration mattered. The WHI used oral conjugated equine estrogens, not transdermal bioidentical estradiol.

This distinction accelerated both research into transdermal formulations and commercial investment in gel products that could be positioned as mechanistically different from the WHI regimen. Divigel and Elestrin entered late-stage development during and immediately after the WHI controversy. Their approval in 2006-2007 was in some ways shaped by the clinical need for safer-profile alternatives.

The VTE Evidence: Why Route of Delivery Matters for Women's Safety

This is the most clinically significant safety distinction between oral estrogen and transdermal gel, and the data are consistent across observational studies.

A 2019 meta-analysis by Vinogradova et al., published in The BMJ, analyzed data from two large UK primary care databases covering 80,396 women with VTE and 391,494 matched controls. Oral estrogen was associated with approximately twice the risk of VTE compared with non-use (odds ratio approximately 1.58 for CEE, 2.07 for oral estradiol). Transdermal estradiol at standard doses showed no statistically significant increase in VTE risk (odds ratio 0.93, 95% CI 0.87-1.01). This is the largest and most methodologically rigorous dataset yet assembled on this question.

The biological explanation maps directly to the mechanism described above. Transdermal delivery avoids the hepatic first-pass synthesis of procoagulant proteins. Oral estrogen does not.

For women with a personal history of VTE, thrombophilia, obesity, or prolonged immobility, this pharmacokinetic difference is not academic. It shapes prescribing decisions. The Menopause Society (formerly NAMS) 2022 Position Statement acknowledges that transdermal estrogen may be preferred in women at elevated VTE risk, though it stops short of recommending transdermal as the universal default.

What the Evidence Does Not Yet Prove

Randomized controlled trials directly comparing transdermal versus oral estradiol for VTE endpoints in women have not been completed at scale. The ESTHER study, a French case-control study, provided early supportive data, but the Vinogradova meta-analysis remains observational. Women and clinicians should understand that the VTE advantage of transdermal gel is supported by strong epidemiological evidence, not yet by a large prospective RCT designed with VTE as the primary endpoint. That distinction matters when weighing individual risk.

Life Stage Considerations

Perimenopause

During perimenopause, estradiol levels fluctuate erratically rather than declining smoothly. Many women in their mid-40s experience hot flushes, sleep disruption, and cycle irregularity while still menstruating. Transdermal estradiol gel is not FDA-approved as a contraceptive, and perimenopausal women using it must use reliable contraception if pregnancy is not desired. The gel will suppress endogenous estradiol fluctuations to some extent but will not reliably block ovulation in women who are still cycling.

A progestogen is also required in perimenopausal women with a uterus when using systemic estrogen, to prevent unopposed estrogen stimulation of the endometrium and reduce risk of endometrial hyperplasia.

Postmenopause

Divigel and Elestrin are FDA-approved for postmenopausal vasomotor symptoms. This is the population in which key trials were conducted. Postmenopausal women with a uterus require concurrent progestogen, typically micronized progesterone 200 mg nightly for 12 days per month or 100 mg nightly continuously.

Women with PCOS

Women with polycystic ovary syndrome who are transitioning toward menopause may have a different baseline hormonal profile, with higher LH and androgen levels, that complicates symptom attribution. There are no PCOS-specific trials of estradiol gel for vasomotor symptoms, so evidence is extrapolated from general postmenopausal populations. Women with PCOS and insulin resistance may also have elevated baseline VTE risk due to metabolic and inflammatory factors, making the lower VTE profile of transdermal gel particularly relevant.

Women with Premature Ovarian Insufficiency

Women diagnosed with premature ovarian insufficiency (POI) before age 40 require estrogen replacement for both symptom management and long-term bone and cardiovascular protection, often at higher doses than used in typical menopause. Transdermal gel is a reasonable route, though the evidence base in POI is thinner than in natural menopause. ACOG Practice Bulletin No. 234 on POI recommends hormone replacement until at least the average age of natural menopause.

Pregnancy, Lactation, and Contraception

Estradiol gel is contraindicated in pregnancy. Exogenous estrogen during pregnancy carries risks of teratogenicity based on animal data and on historical evidence from exposure to synthetic estrogens such as diethylstilbestrol. The FDA assigns estradiol to a category consistent with contraindication in pregnancy based on these signals. If a woman discovers she is pregnant while using estradiol gel, the product should be discontinued immediately and obstetric care sought.

The following framework summarizes reproductive safety for transdermal estradiol gel across three clinical scenarios:

Trying to conceive: Stop the gel before attempting conception. Estradiol gel is not a fertility treatment; exogenous estrogen suppresses the hypothalamic-pituitary-ovarian axis and can interfere with natural follicular development. Women being evaluated for infertility should disclose all hormone use to their reproductive endocrinologist.

Perimenopausal women still at risk of pregnancy: As noted above, estradiol gel does not provide contraception. Women in the perimenopausal transition remain at pregnancy risk until 12 consecutive months of amenorrhea have elapsed (the clinical definition of menopause). Reliable contraception, such as a levonorgestrel IUD (which also provides the required endometrial protection), low-dose combined oral contraceptive (if no contraindications), or barrier methods, is required.

Lactation: Estrogen suppresses prolactin secretion and can reduce milk supply. Estradiol gel should not be used during breastfeeding. Transfer of estradiol into breast milk occurs, and the developmental effects on a nursing infant have not been adequately studied. Women who are postpartum and experiencing hot flushes related to postpartum hormonal shifts should discuss the timing and appropriateness of any hormone therapy initiation with their clinician.

Female-Specific Conditions This Drug Touches

Transdermal estradiol gel is relevant to several female-specific conditions beyond straightforward menopause symptom management.

Genitourinary syndrome of menopause (GSM): Systemic transdermal estradiol, at doses used for vasomotor symptoms, will improve vaginal dryness, urinary urgency, and dyspareunia for many women. However, very low-dose vaginal estrogen is often more targeted and sufficient for women whose primary complaint is genitourinary rather than vasomotor.

Osteoporosis prevention: Estrogen deficiency drives accelerated bone loss in the years immediately surrounding menopause. The Menopause Society notes that systemic hormone therapy is an effective option for fracture prevention in women at elevated bone-loss risk, particularly those under age 60 or within 10 years of menopause onset. Transdermal estradiol maintains bone density, though it is not specifically FDA-approved as an osteoporosis treatment.

Hormonal migraine: Women with menstrual migraine driven by the perimenstrual estradiol withdrawal may benefit from transdermal estradiol gel used as a short-cycle "add-back" strategy around menstruation. This is an off-label use supported by evidence from small trials in women with predictable menstrual migraine. Migraine with aura remains a contraindication to combined hormonal contraceptives but is generally not a contraindication to low-dose transdermal estradiol.

Female pattern hair loss: Estrogen's role in hair follicle cycling means that estrogen withdrawal at menopause can trigger or accelerate female pattern hair loss. Whether systemic transdermal estradiol directly improves hair density is not established by high-quality trials; the evidence is observational and mixed.

Who This Is Right For, and Who Should Think Twice

Women Most Likely to Benefit

Transdermal estradiol gel is a strong candidate for women who:

• Have at least seven moderate-to-severe hot flushes per day and want FDA-approved treatment
• Have elevated VTE risk factors (prior clot, thrombophilia, BMI >30, prolonged immobility) that make oral estrogen a less favorable choice
• Dislike or cannot tolerate the adhesive skin reactions associated with patches
• Prefer a once-daily application without a visible device
• Have a history of triglyceride elevation, because transdermal delivery does not raise triglycerides the way oral estrogen can

Women Who Should Approach With Caution or Avoid

Estradiol gel is not appropriate for women with:

• Active or recent breast cancer (hormone-receptor positive) or endometrial cancer
• Unexplained vaginal bleeding
• Active liver disease or significantly impaired hepatic function
• A current DVT, PE, or arterial thromboembolic event (though the long-term risk with transdermal appears lower than oral, acute events remain a contraindication)
• Pregnancy (contraindicated; see above)

Women with a BRCA1 or BRCA2 mutation who have had risk-reducing salpingo-oophorectomy have a specific risk-benefit calculation that should involve a genetics counselor, gynecologic oncologist, and menopause specialist working together.

Application, Absorption Variables, and a Practical Note on Alcohol Interactions

Applying gel to areas that are wet, recently shaved, or covered in lotion reduces absorption unpredictably. Serum estradiol levels can vary by as much as 30% between application to intact versus recently irritated skin.

Alcohol consumption raises endogenous and exogenous estradiol levels in women by impairing hepatic estradiol clearance. Women using transdermal estradiol gel should know that heavy alcohol use may push serum estradiol above the intended therapeutic range, an effect that is pharmacologically relevant but rarely discussed in patient education materials. The NIH National Cancer Institute has published data showing alcohol raises circulating estradiol in postmenopausal women on hormone therapy.

The gel must not be applied to the breasts or face. Transfer to partners or children through skin contact is a documented safety concern; the gel should be fully dry before skin-to-skin contact.